Lupin has posted its performance for the second quarter ended September30, 2013. These unaudited results were taken on record by the Board of Directors at a recently held meeting in Mumbai. The net sales grew by 18 per cent to Rs 26,315 million during Q2, FY 2013-14, up from Rs 22,393 million (Q2, FY 2012-13). The EBITDA margin grew by 42 per cent to Rs 7,410 million. during Q2, FY 2013-14, up from Rs 5,202 million (Q2, FY 2012-13). The profit before tax grew by 53 per cent to Rs 6,755 million during Q2, FY 2013-14, up from Rs 4,412 million (Q2, FY 2012-13). The net profit grew by 40 per cent to Rs 4,062 million during Q2, FY 2013-14, up from Rs 2,905 million (Q2, FY 2012-13).
The Indian formulations business contributed 25 per cent of the company’s overall revenues for the quarter. The company’s India formulation business grew by nine per cent recording revenues of Rs 6,635 million during Q2, FY 2013-14, as compared to Rs 6,064 million for Q2, FY 2012-13.
Nilesh Gupta, Managing Director, Lupin, said, “Despite challenges in markets like India, we have had a good first half, driven by strong business growth from markets like the US and improved operational efficiencies. Our growth story continues. This consistent performance has led to a sustained EBIDTA and PAT improvement.”
EP News Bureau – Mumbai
